Hoogendijk Raoull, van der Lugt Jasper, van Vuurden Dannis, Kremer Leontien, Wesseling Pieter, Hoving Eelco, Karim-Kos Henrike E
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Department of Pediatrics, Emma Children's Hospital/Amsterdam University Medical Center/AMC, Amsterdam, the Netherlands.
Neurooncol Adv. 2021 Dec 21;4(1):vdab183. doi: 10.1093/noajnl/vdab183. eCollection 2022 Jan-Dec.
Survival of children with central nervous system (CNS) tumors varies largely between countries. For the Netherlands, detailed population-based estimation of incidence, survival, and mortality of pediatric CNS tumors are lacking but are needed to evaluate progress.
All CNS tumors diagnosed in patients <18 years during 1990-2017 were selected from the Netherlands Cancer Registry. Other than pilocytic astrocytomas, nonmalignant tumors were included since 2000. Incidence and mortality trends were evaluated by average annual percentage change (AAPC). Changes over time in the five-year observed survival (5-year OS) were evaluated by Poisson regression models adjusted for follow-up time.
Between 1990 and 2017, 2057 children were diagnosed with a malignant CNS tumor and 885 with a pilocytic astrocytoma. During 2000-2017, 695 children were diagnosed with other nonmalignant CNS tumors. Incidence rates of malignant tumors remained stable, while pilocytic astrocytomas and other nonmalignant tumors increased by 2.0% and 2.4% per year, respectively. The 5-year OS rates improved for all groups; however, improvement for malignant tumors was not constant over time. The contribution of malignant tumors located at the optic nerve tumors was 1% in 2000-2009. However, shifting from pilocytic astrocytomas, increased to 6% in 2010-2017, impacting survival outcomes for malignant tumors.
Survival rates of CNS tumors improved over time but were not accompanied by a decreasing mortality rate. The observed temporary survival deterioration for malignant tumors appears to be related to changes in diagnostics and registration practices. Whether differences in treatment regimens contribute to this temporary decline in survival needs to be verified.
中枢神经系统(CNS)肿瘤患儿的生存率在不同国家差异很大。在荷兰,缺乏基于详细人群的小儿中枢神经系统肿瘤发病率、生存率和死亡率的估计,但评估进展情况需要这些数据。
从荷兰癌症登记处选取1990 - 2017年期间诊断出的所有18岁以下患者的中枢神经系统肿瘤。自2000年起,除毛细胞性星形细胞瘤外,非恶性肿瘤也被纳入。发病率和死亡率趋势通过平均年度百分比变化(AAPC)进行评估。五年观察生存率(5年OS)随时间的变化通过调整随访时间的泊松回归模型进行评估。
1990年至2017年期间,2057名儿童被诊断患有恶性中枢神经系统肿瘤,885名患有毛细胞性星形细胞瘤。2000年至2017年期间,695名儿童被诊断患有其他非恶性中枢神经系统肿瘤。恶性肿瘤的发病率保持稳定,而毛细胞性星形细胞瘤和其他非恶性肿瘤分别以每年2.0%和2.4%的速度增长。所有组的5年OS率均有所提高;然而,恶性肿瘤的改善情况随时间并不恒定。视神经肿瘤中的恶性肿瘤在2000 - 2009年的占比为1%。然而,从毛细胞性星形细胞瘤转变后,在2010 - 2017年增加到6%,影响了恶性肿瘤的生存结果。
中枢神经系统肿瘤的生存率随时间有所提高,但并未伴随着死亡率的下降。观察到的恶性肿瘤生存率的暂时恶化似乎与诊断和登记做法的变化有关。治疗方案的差异是否导致了这种生存的暂时下降有待验证。